Skip to Content

Atenolol Pregnancy and Breastfeeding Warnings

Atenolol is also known as: Tenormin

Atenolol Pregnancy Warnings

Atenolol crosses the placental barrier and appears in cord blood. Administration of this drug during the second trimester of pregnancy has been associated with small for gestational age births; this may be for related to duration of use. There are no studies for use in the first trimester, however, infant risk cannot be ruled out. Beta-blocker use has been associated with decreased placental perfusion which may lead to intra-uterine deaths, immature and premature deliveries. Neonates exposed to this drug during the third trimester are at risk for adverse reactions due to beta-blockade. There are no adequate and well-controlled studies in pregnant women. US FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite risks. AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details.

Use during pregnancy only if the benefit outweighs risk US FDA pregnancy category: D AU TGA pregnancy category: C Comments: -Apprise women of potential risk to fetus if pregnant or become pregnant while taking this drug. -After birth, monitor infants for the signs of beta blockade, generally expected in first 3 days.

See references

Atenolol Breastfeeding Warnings

Use with caution Excreted into human milk: Yes Comments: -Clinically significant bradycardia has occurred; monitor breastfed infants, especially newborns and with high maternal doses, for signs of beta blockade.

This drug is excreted into human breast milk at a ratio of 1.5 to 6.8 when compared to the plasma concentration. Signs of beta blockade, such as bradycardia, hypotension, and hypoglycemia, have been observed in breastfed infants. Neonates younger than 3 months of age, infants with impaired renal function, and high maternal doses, are at increased risk due to high renal excretion of this drug and its potential for accumulation in the breastmilk. The risk in older infants appears to be lower.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. "Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc, Cost Mesa, CA.

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):
  4. "Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc, Cost Mesa, CA.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.